All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-06-16T07:22:20.000Z

Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL

By Claire Baker
Featured
Michael Dickinson
Jun 16, 2020
Share:

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, AU, about the phase I study of CD20-TCB (glofitamab) in relapsed/refractory non-Hodgkin lymphoma.

CD20-TCB is a novel T-cell-engaging bispecific antibody that has demonstrated high potency in the presence of other anti-CD20 antibodies. A phase I dose-escalation study (NCT03075696), evaluating the efficacy, safety, tolerability, and pharmacokinetic profile of CD20-TCB, is currently underway. Here, Michael Dickinson outlines the high response and complete remission rates observed amongst patients receiving active doses of CD20-TCB.

Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL

More about...
Aggressive B-cell lymphomasBurkitt lymphomaDiffuse large B-cell lymphomaEHA 2020Follicular lymphomaGlofitamabIndolent B-cell lymphomasMantle cell lymphomaMantle cell lymphomasNP30179T-cell engagers

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Results from a phase I/Ib dose-escalation study of mosunetuzumab in high-risk non-Hodgkin lymphoma patients

During the plenary session at the 61st ASH Annual Meeting & Exposition, Stephen Schuster presented the phase I/Ib dose-escalation and...

Jan 7, 2020
Add bookmark

Results from a phase I/Ib dose-escalation study of mosunetuzumab in high-risk non-Hodgkin lymphoma patients

During the plenary session at the 61st ASH Annual Meeting & Exposition, Stephen Schuster...

Jan 7, 2020
Add bookmark

TCT Meeting 2019 | Nicotinamide-expanded related donor natural killer cells for the treatment of relapsed/refractory multiple myeloma and non-Hodgkin lymphoma: results from the first-in-human phase I study

results from the first-in-human phase I...

Mar 12, 2019
Add bookmark

TCT Meeting 2019 | Nicotinamide-expanded related donor natural killer cells for the treatment of relapsed/refractory multiple myeloma and non-Hodgkin lymphoma: results from the first-in-human phase I...

Mar 12, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox